nach oben

Erschienen in:

27.01.2022 | Original Article

Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients

verfasst von: Gabriele Sorce, Rocco Simone Flammia, Benedikt Hoeh, Francesco Chierigo, Benedikt Horlemann, Christoph Würnschimmel, Zhe Tian, Markus Graefen, Carlo Terrone, Michele Gallucci, Felix K. H. Chun, Fred Saad, Shahrokh F. Shariat, Francesco Montorsi, Alberto Briganti, Pierre I. Karakiewicz

Erschienen in: World Journal of Urology | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Data about optimal management of plasmacytoid (PCV) bladder cancer patients are extremely scarce and limited by sample size. We focused on PCV bladder cancer patients to explore the effect of radical cystectomy (RC) and chemotherapy in non-metastatic (T _2–4N_0–3M₀), as well as in metastatic (T_anyN_anyM₁) subgroups.

Methods

Using the Surveillance, Epidemiology and End Results database (2000–2016), we identified 332 PCV patients with muscle-invasive disease or higher (≥ T₂N₀M₀). Kaplan–Meier plots and Cox regression models addressed cancer-specific mortality (CSM).

Results

In 332 PCV patients, median age was 68 years (Interquartile range [IQR]:58–76). Of those, 252 were non-metastatic patients (76%) vs 80 were metastatic patients (24%), at presentation. Of non-metastatic patients, 142 (56%) underwent RC and 131 (52%) underwent chemotherapy. Chemotherapy did not improve CSM in non-metastatic PCV. Conversely, RC was associated with lower CSM (hazard ratio [HR]: 0.51, p = 0.002). Median CSM-free survival was 48 vs 38 months for RC treated vs RC not treated. Of metastatic patients, 22 (28%) underwent RC and 42 (52%) underwent chemotherapy. Both chemotherapy and RC improved CSM in metastatic PCV. Median CSM-free survival was 12 vs 7 months for RC treated vs RC not treated (HR: 0.27, p < 0.001). Median CSM-free survival was 11 vs 4 months for chemotherapy exposed vs chemotherapy naïve (HR: 0.32, p = 0.002).

Conclusions

Although RC resulted in lower CSM, chemotherapy failed to show that effect in non-metastatic PCV patients. Conversely, both chemotherapy and RC resulted in statistically significantly lower CSM in metastatic PCV patients.

Nur mit Berechtigung zugänglich

Keck B, Wach S, Stoehr R, Kunath F, Bertz S, Lehmann J et al (2013) Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer. https://doi.org/10.1186/1471-2407-13-71CrossRefPubMedPubMedCentral

Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP et al (2013) Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 189:1656–1661. https://doi.org/10.1016/j.juro.2012.11.084CrossRefPubMed

Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1311593CrossRefPubMedPubMedCentral

Kim DK, Kim JW, Ro JY, Lee HS, Park JY, Ahn HK et al (2020) Plasmacytoid variant urothelial carcinoma of the bladder: A systematic review and meta-analysis of clinicopathological features and survival outcomes. J Urol 204:215–223. https://doi.org/10.1097/JU.0000000000000794CrossRefPubMed

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs—part b: prostate and bladder tumours. Eur Urol 70:106–119. https://doi.org/10.1016/j.eururo.2016.02.028CrossRefPubMed

Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L et al (2015) Contemporary bladder cancer: Variant histology may be a significant driver of disease. Urol Oncol Semin Orig Investig 33:18.e15-18.e20. https://doi.org/10.1016/j.urolonc.2014.10.001CrossRef

Kaimakliotis HZ, Monn MF, Cary KC, Pedrosa JA, Rice K, Masterson TA et al (2014) Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm? Urol Oncol Semin Orig Investig 32:833–838. https://doi.org/10.1016/j.urolonc.2014.03.008CrossRef

Hayashi T, Tanigawa G, Fujita K, Imamura R, Nakazawa S, Yamamoto Y et al (2011) Two cases of plasmacytoid variant of urothelial carcinoma of urinary bladder: Systemic chemotherapy might be of benefit. Int J Clin Oncol 16:759–762. https://doi.org/10.1007/s10147-011-0240-4CrossRefPubMed

Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A et al (2020) What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus 6:653–663. https://doi.org/10.1016/j.euf.2019.09.003CrossRefPubMed

10.

Kohno T, Kitamura M, Akai H, Takaha M, Kawahara K, Oka T (2006) Plasmacytoid urothelial carcinoma of the bladder. Int J Urol 13:485–486. https://doi.org/10.1111/j.1442-2042.2006.01338.xCrossRefPubMed

11.

Diamantopoulos LN, Khaki AR, Grivas P, Gore JL, Schade GR, Hsieh AC et al (2020) Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. Bl Cancer 6:71–81. https://doi.org/10.3233/BLC-190258CrossRefPubMed

12.

Hashemi-Sadraei N, Perrino CM, Monn MF, Bandali E, Cheng L, Idrees M et al (2018) Plasmacytoid urothelial carcinoma: A clinicopathological study. J Clin Oncol 36:482–482. https://doi.org/10.1200/jco.2018.36.6_suppl.482CrossRef

13.

Teo MY, Al-Ahmadie H, Seier K, Tully C, Regazzi AM, Pietzak E et al (2021) Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. Br J Cancer 124:1214–1221. https://doi.org/10.1038/s41416-020-01244-2CrossRefPubMedPubMedCentral

14.

Ericson KJ, Thomas L, Lee BH (2019) Plasmacytoid variant urothelial carcinoma: Clinicopathologic outcomes and experience with neoadjuvant chemotherapy. J Clin Oncol 37:483–483. https://doi.org/10.1200/jco.2019.37.7_suppl.483CrossRef

15.

Li Q, Assel M, Benfante NE, Pietzak EJ, Herr HW, Donat M et al (2019) The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy. Eur Urol Focus 5:104–108. https://doi.org/10.1016/j.euf.2017.06.013CrossRefPubMed

16.

Ro JY, Shen SS, Lee HI, Hong EK, Lee YH, Cho NH et al (2008) Plasmacytoid transitional cell carcinoma of urinary bladder: A clinicopathologic study of 9 cases. Am J Surg Pathol 32:752–757. https://doi.org/10.1097/PAS.0b013e318159af9eCrossRefPubMed

17.

Nigwekar P, Tamboli P, Amen MB, Osunkoya AO, Ben-Dor D, Amin MB (2009) Plasmacytoid urothelial carcinoma: Detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol 33:417–424. https://doi.org/10.1097/PAS.0b013e318186c45eCrossRefPubMed

18.

Cancer Statistics Review, 1975–2018 - SEER Statistics n.d. https://seer.cancer.gov/csr/1975_2018/ (accessed June 10, 2001)

19.

AJCC Cancer Staging Manual | Mahul B. Amin | Springer n.d. https://www.springer.com/gp/book/9783319406176 (accessed July 4, 2001)

20.

R: The R Project for Statistical Computing n.d. https://www.r-project.org/ (accessed June 15, 2001)

21.

Cockerill PA, Cheville JC, Boorjian SA, Blackburne A, Thapa P, Tarrell RF et al (2017) Outcomes following radical cystectomy for plasmacytoid urothelial carcinoma: defining the need for improved local cancer control. Urology 102:143–147. https://doi.org/10.1016/j.urology.2016.09.053CrossRefPubMed

22.

Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM et al (2019) What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? a european association of urology mus. Eur Urol Oncol 2:625–642. https://doi.org/10.1016/j.euo.2019.09.003CrossRefPubMed

23.

Wang J, Wang FW (2011) Clinical characteristics and outcomes of patients with primary signet-ring cell carcinoma of the urinary bladder. Urol Int 86:453–460. https://doi.org/10.1159/000324263CrossRefPubMed

24.

Wu SG, Chen XT, Zhang WW, Sun JY, Li FY, He ZY et al (2018) Survival in signet ring cell carcinoma varies based on primary tumor location: a surveillance, epidemiology, and end results database analysis. Expert Rev Gastroenterol Hepatol 12:209–214. https://doi.org/10.1080/17474124.2018.1416291CrossRefPubMed

25.

Patel SG, Weiner AB, Keegan K, Morgan T (2018) Oncologic outcomes in patients with nonurothelial bladder cancer. Indian J Urol 34:39–44. https://doi.org/10.4103/iju.IJU_115_17CrossRefPubMedPubMedCentral

26.

Jue JS, Koru-Sengul T, Moore KJ, Miao F, Alameddine M, Nahar B et al (2018) Sociodemographic and survival disparities for histologic variants of bladder cancer. Can J Urol 25:9179–9185PubMed

27.

Jin D, Qiu S, Jin K, Zhou X, Cao Q, Yang L et al (2020) Signet-ring cell carcinoma as an independent prognostic factor for patients with urinary bladder cancer: a population-based study. Front Oncol 10:653. https://doi.org/10.3389/fonc.2020.00653CrossRefPubMedPubMedCentral

28.

Deuker M, Martin T, Stolzenbach F, Rosiello G, Collà Ruvolo C, Nocera L et al (2021) Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. Clin Genitourin Cancer 19:60-68.e1. https://doi.org/10.1016/j.clgc.2020.07.011CrossRefPubMed

29.

Mazzone E, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G et al (2019) More extensive lymph node dissection improves survival benefit of radical cystectomy in metastatic urothelial carcinoma of the bladder. Clin Genitourin Cancer 17:105-113.e2. https://doi.org/10.1016/j.clgc.2018.11.003CrossRefPubMed

30.

Seisen T, Sun M, Leow JJ, Preston MA, Cole AP, Gelpi-Hammerschmidt F et al (2016) Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: A propensity score-weighted analysis from the National Cancer Data Base. J Clin Oncol 34:3529–3536. https://doi.org/10.1200/JCO.2016.66.7352CrossRefPubMed

Titel: Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients
verfasst von: Gabriele Sorce
Rocco Simone Flammia
Benedikt Hoeh
Francesco Chierigo
Benedikt Horlemann
Christoph Würnschimmel
Zhe Tian
Markus Graefen
Carlo Terrone
Michele Gallucci
Felix K. H. Chun
Fred Saad
Shahrokh F. Shariat
Francesco Montorsi
Alberto Briganti
Pierre I. Karakiewicz
Publikationsdatum: 27.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2022
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-022-03940-5

Neu im Fachgebiet Urologie

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Operation bei Blasenkrebs/© anistidesign / Fotolia, Medizinische Fachangestellte sitzt erschöpft auf der Treppe/© Courtney Haas / peopleimages.com /stock.adobe.com (Symbolbild mit Fotomodell), Glomerulationen bei interstitieller Zystitis/© Tolle, J., Kaftan, B.T. & Bschleipfer, T. / all rights reserved Springer Medizin Verlag GmbH, Darstellung der Dosisverteilung bei Bestrahlung eines Prostatakarzinoms/© Degener, S et al. / all rights reserved Springer Medizin Verlag GmbH

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Prospective randomized controlled trial comparing a ureteral stent crossing versus not crossing the bladder midline

Association between use of ERAS protocols and complications after radical cystectomy

Day-case robotic-assisted partial nephrectomy: feasibility and preliminary results of a prospective evaluation (UroCCR-25 AMBU-REIN study)

T2 mapping for the characterization of prostate lesions